Ciluprevir

Ciluprevir
Clinical data
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	Development terminated;
Pharmacokinetic data
Protein binding	>99.1%
Identifiers
	IUPAC name (2R,6S,12Z,13aS,14aR,16aS)-6-[(Cyclopentyloxycarbonyl)amino]-2-({7-methoxy-2-[(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin- 4-yl}oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid;
CAS Number	300832-84-2;
PubChem CID	9853710;
ChemSpider	8029420;
UNII	75C8DU40T0;
ChEMBL	ChEMBL297884;
CompTox Dashboard (EPA)	DTXSID50870316 ;
Chemical and physical data
Formula	C40H50N6O8S
Molar mass	774.93 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N[C@]7(C(=O)O)C[C@H]7/C=C\CCCCC[C@H](NC(=O)OC1CCCC1)C(=O)N6[C@H]2C[C@@H](Oc3cc(nc4c3ccc(OC)c4)c5nc(sc5)NC(C)C)C6;
	InChI InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24-,27-,29+,33+,40-/m1/s1; Key:PJZPDFUUXKKDNB-KNINVFKUSA-N;

Ciluprevir was a drug used experimentally in the treatment of hepatitis C. It is manufactured by Boehringer Ingelheim and developed under the research code of BILN 2061. It was the first-in-class NS3/4A protease inhibitor to enter clinical development and tested in human.^[2] Ciluprevir is a potent competitive reversible inhibitor of NS3/4A protease from HCV genotype 1a (K_i = 0.3 nM) and 1b (K_i = 0.66 nM). It shows good selectivity for NS3 protease against representative serine and cysteine proteases, human leukocyte elastase and cathepsin B (IC₅₀ > 30 μM).^[1]

Its development was halted in phase Ib clinical trials because of toxicity in animals. However, ciluprevir scaffold was exploited to design new macrocyclic inhibitors such as simeprevir (TMC-435) and danoprevir.^[3]

References

^ ^a ^b Tan, Seng-Lai; He, Yupeng, eds. (2011). Hepatitis C: Antiviral Drug Discovery and Development. Norfolk, UK: Caister Academic Press. p. 199. ISBN 978-1-904455-78-3.
^ Tan, Seng-Lai, ed. (2006). "6. HCV NS3-4A Serine Protease". Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience. ISBN 978-1-904933-20-5.
^ Chatel-Chaix, L; Baril, M; Lamarre, D (August 2010). "Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel". Viruses. 2 (8): 1752–65. doi:10.3390/v2081752. PMC 3185733. PMID 21994705.{{cite journal}}: CS1 maint: unflagged free DOI (link)

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[Tan-1] Tan, Seng-Lai; He, Yupeng, eds. (2011). Hepatitis C: Antiviral Drug Discovery and Development. Norfolk, UK: Caister Academic Press. p. 199. ISBN 978-1-904455-78-3.

[2] Tan, Seng-Lai, ed. (2006). "6. HCV NS3-4A Serine Protease". Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience. ISBN 978-1-904933-20-5.

[3] Chatel-Chaix, L; Baril, M; Lamarre, D (August 2010). "Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel". Viruses. 2 (8): 1752–65. doi:10.3390/v2081752. PMC 3185733. PMID 21994705.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[1]

[2]

[3]